OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Haematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes	61
CAR T and CAR NK cells in multiple myeloma: Expanding the targets	38
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action	27
Molecular markers in ALL: Clinical implications	27
Second malignancies in multiple myeloma; emerging patterns and future directions	26
COVID-19 disease and immune dysregulation	25
Immunologic effects on the haematopoietic stem cell in marrow failure	23
Reconstructing the evolutionary history of multiple myeloma	19
The promise of macrophage directed checkpoint inhibitors in myeloid malignancies	17
Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood	15
Treatment of telomeropathies	15
Immune checkpoint inhibitors in acute myeloid leukemia	15
CD33 directed bispecific antibodies in acute myeloid leukemia	15
Perspectives on current survival and new developments in AML	14
Acute myeloid leukemia and artificial intelligence, algorithms and new scores	14
Juvenile myelomonocytic leukemia – A bona fide RASopathy syndrome	13
Autoimmune disease in CMML-the chicken or the egg?	12
Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax	12
CD123 bi-specific antibodies in development in AML: What do we know so far?	12
Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management	12
Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome	11
Distinguishing constitutional from acquired bone marrow failure in the hematology clinic	11
TCR gene-engineered cell therapy for solid tumors	11
Have any strategies in Ph-like ALL been shown to be effective?	10
COVID-19 and antiphospholipid antibodies	10

Toxicities associated with adoptive cellular therapies	9
Monitoring minimal residual disease in the bone marrow using next generation sequencing	9
Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage	9
Congenital amegakaryocytic thrombocytopenia – Not a single disease	9
Somatic mosaicism in inherited bone marrow failure syndromes	9
Mechanisms of thrombosis in pancreatic ductal adenocarcinoma	9
Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia	9
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications	9
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia	9
Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime?	8
GATA2 and marrow failure	8
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?	8
COVID-19 and HSCT (Hematopoietic stem cell transplant)	8
Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders	8
Molecular genetics of MDS/MPN overlap syndromes	7
Blood coagulation and cancer genes	7
Tracking myeloma tumor DNA in peripheral blood	7
Genomic profiling of multiple myeloma: New insights and modern technologies	7
New targets for CAR T therapy in hematologic malignancies	7
WGS and WTS in leukaemia: A tool for diagnostics?	7
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?	7
The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies—back to the future!	7
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future	7
Thrombosis and bleeding in hematological malignancy	7
Clinical experience of CAR T cells for multiple myeloma	7
Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?	6
Vaccine-induced immune thrombotic thrombocytopenia	6
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents	6
CML - Not only BCR-ABL1 matters	6
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults	6
Modern treatments and future directions for newly diagnosed multiple myeloma patients	6
Clonal hematopoiesis and bone marrow failure syndromes	6
Atypical CML- the role of morphology and precision genomics	6
Bone marrow transplantation for acquired aplastic anemia: What's new	5
Accelerated and blast phase myeloproliferative neoplasms	5
Overcoming graft failure after haploidentical transplantation: Is this a possibility?	5
Antibody based therapy in relapsed acute lymphoblastic leukemia	5
Cytogenetics in the genomic era	5
Spliceosomal factor mutations and mis-splicing in MDS	5
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care	5
Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a “catch-all” term?	5
Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci	5
Myeloproliferative neoplasms in adolescents and young adults	4
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia	4
It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS	4
Challenges in anticoagulation for patients with brain tumors	4
How old is too old for a transplant?	4
Marrow failure and aging: The role of “Inflammaging”	4
Dysregulation of Protein S in COVID-19	4
Advances in polycythemia vera and lessons for acute leukemia	4

Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults	4
Advances in CAR design	4
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults	4
Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?	4
Contemporary treatment approaches to CMML – Is allogeneic HCT the only cure?	4
A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition	3
Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps	3
Coagulopathy in COVID-19 and anticoagulation clinical trials	3
Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome	3
Progress in the management of chronic GVHD insights into novel therapies to treat and manage GVHD lasting longer than 12 Months	3
Which novel agents will have a clinically meaningful impact in AML at diagnosis?	3
A review of latest clinical practice guidelines for the management of cancer-associated thrombosis	3
Changing trends in the therapy of acute myeloid leukemia	3
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia	3
What are the molecular mechanisms driving the switch from MPNs to leukemia?	3
Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL)	3
Monoclonal antibodies in frontline acute lymphoblastic leukemia	3
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma	3
CAR T in adult ALL: When and for whom?	2
Treatment modalities in cancer-associated venous thromboembolism (VTE)	2
Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma	2
Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant?	2
Molecular alterations governing predisposition to myelodysplastic syndromes: Insights from Shwachman-Diamond syndrome	2
Challenges of diagnosing and managing pre-fibrotic myelofibrosis: A case-based and practical approach	2
Thrombopoietin receptor agonists for marrow failure: A concise clinical review	2
Hypomethylating agents as maintenance therapy following allogeneic hematopoietic cell transplantation for myeloid malignancies	2
Measurable disease evaluation in patients with myeloma	2
Moving towards a uniform risk stratification system in CMML - How far are we?	2
Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?	2
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms	2
Founder and subclonal mutations in myelodysplastic syndromes and related myeloid neoplasms	2
How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?	2
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma	2
Cancer associated thrombosis in pediatric patients	2
The potential role of Bi-specific antibodies in acute myeloid leukemia	2
A perspective on the sickle cell disease international COVID-19 registry	1
Recent progress in acute leukemia and myelodysplasia	1
MDS/MPN-RS-T justified inclusion as a unique disease entity?	1
Managing older adults with Ph-negative ALL: What is new? Recent advances in treating older adults with ALL	1
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies	1
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program	1
Bone marrow failure syndromes	1
Addressing symptom burden in myeloproliferative neoplasms	1
Multiple myeloma: Current advances and future directions	1
COVID-19 outcomes in sickle cell disease and sickle cell trait	1
How can we incorporate molecular data into the IPSS?	1
Preface	1
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma	1
What is the role of the bone marrow microenvironment in AML?	1
How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML	1
Is there an optimal adjunct therapy to traditional cytotoxic induction?	1
Since everyone has a donor, why are some eligible patients still not transplanted?	1
Novel therapeutic targets for chronic myelomonocytic leukemia	1
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-19	1
Will immunotherapy lead to a breakthrough in the treatment of older adults with ALL?	1
Clinical experience of CAR T cell therapy in lymphomas	1
Principles of cost-effectiveness studies and their use in haematology	1
Is the current consolidation regimen for AML evidence-based?	1
Improving clinical trials in higher-risk myelodysplastic syndromes	1
Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?	1
Diagnosis and management of cutaneous lymphomas and lymphoid proliferations in children, adolescents and young adults (CAYA)	1
Acute GVHD: New approaches to clinical trial monitoring	1
Transplantation algorithm for myelofibrosis in 2022 and beyond	1
The role of randomized controlled trials, registries, observational databases in evaluating new interventions	1
Contemporary and future strategies in polycythemia vera	1
Financial toxicity in patients with leukemia undergoing hematopoietic stem cell transplantation: A systematic review	1
Graft versus Leukemia in 2023	1